Notable Upgrades: Juno Therapeutics (JUNO), FireEye (FEYE), Incyte (INCY), Cigna Corp. (CI)

In a report published Tuesday, FBR Capital analysts initiated coverage on Juno Therapeutics Inc. (JUNO) with a ‘Outperform‘ rating and $73 price target. Currently, there are 4 analysts that rate JUNO a ‘Buy’ vs. 3 rating it a ‘Hold’. No analyst rates it a ‘Sell’. The name has a median Wall Street price target of […] View the full post at: Notable Upgrades: Juno Therapeutics (JUNO), FireEye (FEYE), Incyte (INCY), Cigna Corp. (CI) Related posts: Apache Corp. in final talks to buy Energy Corp’s shallow Gulf assets Koss Corp Discovers Information Regarding Certain Unauthorized Transactions; Stock Halted Bay Area Median Home Prices Up 4.2% in April